Purpose:
The aim of this study was to evaluate and compare the effects of repeated administrations of three prostaglandin F(2alpha) analogs (tafluprost, latanoprost, and travoprost) on optic nerve head (ONH) blood flow in normal rabbits.
Methods:
Male Dutch rabbits were housed under a 12-h light-dark cycle for use in this study. A quantitative index of blood flow, the squared blur rate (SBR), was determined using laser speckle flowgraphy. Saline, 0.0015% tafluprost, 0.005% latanoprost, or 0.004% travoprost (each 50 microL) was topically administered into the left eye once daily for 28 days. ONH blood flow was measured before the start at the course of treatment (baseline), and on day 14 and/or day 28 [measurements being made at 0, 30, and/or 60 min after drugs application on day 14 and/or day 28]. Heart rate was also measured at these time points.
Results:
Tafluprost, latanoprost, and travoprost each increased the ONH blood flow at all measurement points on day 14 and/or day 28. The 0 min SBR value on day 14 was greater than the baseline SBR value by 8.7% + or - 4.4% for tafluprost and by 5.8% + or - 1.7% for latanoprost. The 0 min SBR value on day 28 was greater than the baseline SBR value by 11.9% + or - 3.9% for tafluprost, by 7.2% + or - 4.3% for latanoprost, and by 6.7% + or - 3.5% for travoprost. The increasing state of the ONH blood flow continued within 60 min after a topical administration of tafluprost, latanoprost, or travoprost. Tafluprost, latanoprost, and travoprost did not change heart rate (vs. the baseline value) at any measurement points.
Conclusions:
Repeated topical administration of any of the three prostaglandin F(2alpha) analogs increased ONH blood flow in rabbits, without changing heart rate. The increase in ONH blood flow induced by tafluprost was greater than that induced by latanoprost (P = 0.086) or travoprost (P = 0.037) at 60 min on day 28.
Citing Articles
Nanocarriers for the Delivery of Neuroprotective Agents in the Treatment of Ocular Neurodegenerative Diseases.
Patel C, Pande S, Sagathia V, Ranch K, Beladiya J, Boddu S
Pharmaceutics. 2023; 15(3).
PMID: 36986699
PMC: 10052766.
DOI: 10.3390/pharmaceutics15030837.
The evaluation of the effect of tafluprost on the intraocular pressure of healthy male guinea pigs under different light-and-darkness regimes.
Armin A, Arfaee F, Ozmaie S, Asghari A
Vet Med Sci. 2023; 9(3):1172-1178.
PMID: 36757117
PMC: 10188098.
DOI: 10.1002/vms3.1082.
Effects of Tafluprost on Ocular Blood Flow.
Zhang X, Zhou X, Zhao Y, Yang X, Zhou D, Chen B
Ophthalmol Ther. 2022; 11(6):1991-2003.
PMID: 36109465
PMC: 9587142.
DOI: 10.1007/s40123-022-00566-z.
Neuroaxonal and cellular damage/protection by prostanoid receptor ligands, fatty acid derivatives and associated enzyme inhibitors.
Sharif N
Neural Regen Res. 2022; 18(1):5-17.
PMID: 35799502
PMC: 9241399.
DOI: 10.4103/1673-5374.343887.
Pulse Waveform Analysis of the Ocular Blood Flow Using Laser Speckle Flowgraphy before and after Glaucoma Treatment.
Masai S, Ishida K, Anraku A, Takumi T, Tomita G
J Ophthalmol. 2019; 2019:1980493.
PMID: 31687195
PMC: 6794986.
DOI: 10.1155/2019/1980493.
Assessment of the optic nerve head, peripapillary, and macular microcirculation in the newly diagnosed patients with primary open-angle glaucoma treated with topical tafluprost and tafluprost/timolol fixed combination.
Kurysheva N
Taiwan J Ophthalmol. 2019; 9(2):93-99.
PMID: 31198667
PMC: 6557063.
DOI: 10.4103/tjo.tjo_108_17.
Effects of aqueous suppressants and prostaglandin analogues on early wound healing after glaucoma implant surgery.
Jung K, Woo J, Park C
Sci Rep. 2019; 9(1):5251.
PMID: 30918313
PMC: 6437192.
DOI: 10.1038/s41598-019-41790-1.
Tafluprost Ophthalmic Solution 0.0015 %: A Review in Glaucoma and Ocular Hypertension.
Keating G
Clin Drug Investig. 2016; 36(6):499-508.
PMID: 27225879
DOI: 10.1007/s40261-016-0413-z.
Comparison of Ocular Pulse Amplitude Lowering Effects of Preservative-Free Tafluprost and Preservative-Free Dorzolamide-Timolol Fixed Combination Eyedrops.
Seo D, Ha S
Biomed Res Int. 2015; 2015:435874.
PMID: 26557671
PMC: 4628750.
DOI: 10.1155/2015/435874.
Tafluprost/Timolol: A Review in Open-Angle Glaucoma or Ocular Hypertension.
Hoy S
Drugs. 2015; 75(15):1807-13.
PMID: 26431840
DOI: 10.1007/s40265-015-0476-9.
Pharmacotherapy of glaucoma.
Schmidl D, Schmetterer L, Garhofer G, Popa-Cherecheanu A
J Ocul Pharmacol Ther. 2015; 31(2):63-77.
PMID: 25587905
PMC: 4346603.
DOI: 10.1089/jop.2014.0067.
Targeted delivery of antiglaucoma drugs to the supraciliary space using microneedles.
Kim Y, Edelhauser H, Prausnitz M
Invest Ophthalmol Vis Sci. 2014; 55(11):7387-97.
PMID: 25212782
PMC: 4232008.
DOI: 10.1167/iovs.14-14651.
Effects of antiglaucoma drugs on blood flow of optic nerve heads and related structures.
Mayama C, Araie M
Jpn J Ophthalmol. 2013; 57(2):133-49.
PMID: 23321913
DOI: 10.1007/s10384-012-0220-x.
Tafluprost once daily for treatment of elevated intraocular pressure in patients with open-angle glaucoma.
Liu Y, Mao W
Clin Ophthalmol. 2013; 7:7-14.
PMID: 23293509
PMC: 3533683.
DOI: 10.2147/OPTH.S30951.
A new safety concern for glaucoma treatment demonstrated by mass spectrometry imaging of benzalkonium chloride distribution in the eye, an experimental study in rabbits.
Brignole-Baudouin F, Desbenoit N, Hamm G, Liang H, Both J, Brunelle A
PLoS One. 2012; 7(11):e50180.
PMID: 23209668
PMC: 3507684.
DOI: 10.1371/journal.pone.0050180.
Differential pharmacology and clinical utility of preservative-free tafluprost in the treatment of ocular hypertension and glaucoma.
Ermis S
Clin Ophthalmol. 2012; 6:673-8.
PMID: 22654492
PMC: 3363306.
DOI: 10.2147/OPTH.S24248.
Safety and tolerability of tafluprost in treatment of elevated intraocular pressure in open-angle glaucoma and ocular hypertension.
Pozarowska D
Clin Ophthalmol. 2010; 4:1229-36.
PMID: 21060677
PMC: 2964963.
DOI: 10.2147/OPTH.S6369.